-
公开(公告)号:US20230355594A1
公开(公告)日:2023-11-09
申请号:US18029323
申请日:2021-10-08
申请人: ADS THERAPEUTICS LLC
发明人: Jinsong NI , Rong YANG
IPC分类号: A61K31/439 , A61K47/06 , A61P27/10 , A61K9/00
CPC分类号: A61K31/439 , A61K47/06 , A61P27/10 , A61K9/0048
摘要: A topical ophthalmological composition includes a therapeutically effective amount of a muscarinic receptor antagonist as an active pharmaceutical ingredient; and a semifluorinated alkane, as a liquid vehicle. The topical ophthalmological composition treats an ocular disease.
-
公开(公告)号:US20220362282A1
公开(公告)日:2022-11-17
申请号:US17624516
申请日:2020-06-15
申请人: ADS THERAPEUTICS LLC
发明人: Jinsong NI , Rong YANG
IPC分类号: A61K31/724 , A61K47/02 , A61P27/04
摘要: A method for treating an eye disease of an affected eye includes administering to the affected eye of a subject in need of such treatment a steroidal-androgen-free composition containing a therapeutically effective amount of beta-cyclodextrin derivative. The eye disease can be meibomian gland dysfunction, blepharitis, or dry eye disease. A steroidal-androgen-free composition includes a beta-cyclodextrin derivative as a sole active pharmaceutical ingredient. The steroidal-androgen-free composition is an ophthalmic composition.
-
公开(公告)号:US20210030889A1
公开(公告)日:2021-02-04
申请号:US17065901
申请日:2020-10-08
申请人: ADS Therapeutics LLC
发明人: Jinsong NI , Rong YANG
IPC分类号: A61K47/68 , C07K16/22 , A61K9/08 , A61K9/00 , C07K16/00 , A61K31/496 , A61K39/395
摘要: A method of producing synergistic and enhanced efficacy in treating a disease in a subject includes providing an antibody, the antibody being a classic antibody or a modified biologic molecule that blocks a first target in the subject; providing a drug, the drug being a small molecule agent that blocks the first target or a second target in the subject; connecting the antibody and the drug with a linker to form an Antibody-Drug Synergism (ADS) compound; and treating the disease with the ADS compound. The linker is hydrolyzed in the subject over a certain time so that both the antibody and the drug exert their functions simultaneously, and the ADS compound confers better efficacy than either the antibody or the drug alone due to a synergism of the ADS compound.
-
公开(公告)号:US20230398233A1
公开(公告)日:2023-12-14
申请号:US18034710
申请日:2021-11-03
申请人: ADS THERAPEUTICS LLC
发明人: Jinsong NI , Rong YANG , Wenkui Ken FANG
IPC分类号: A61K47/68 , C07K16/22 , A61K31/573 , A61K9/00
CPC分类号: A61K47/6889 , C07K16/22 , A61K47/6803 , A61K47/6845 , A61K31/573 , A61K9/0048 , C07K2317/94
摘要: An ocular antibody-drug conjugate compound is provided. The compound includes an antibody, the antibody being a classic antibody or a modified biologic molecule that blocks a first target in the subject; a small molecule drug including an alpha agonist or an anti-inflammatory small molecule selected from a steroid, a NSAID, that regulates a second or more target in the subject; and a linker linking the antibody and the small molecule drug. Methods of treating an ocular disease with the antibody drug conjugate compound are also provided. The linker is hydrolyzed in the subject over a certain time so that both the antibody and the steroid exert their functions simultaneously.
-
公开(公告)号:US20240216337A1
公开(公告)日:2024-07-04
申请号:US18287040
申请日:2022-03-31
申请人: ADS THERAPEUTICS LLC
发明人: Wenkui Ken FANG , Jinsong NI , Rong YANG , Van DINH
IPC分类号: A61K31/4178 , A61K9/00 , A61P27/02 , C07D233/90
CPC分类号: A61K31/4178 , A61K9/0048 , A61P27/02 , C07D233/90
摘要: A co-drug or a pharmaceutical salt thereof includes a muscarinic agonist moiety and an alpha2 adrenergic agonist moiety. The muscarinic agonist moiety and the alpha2 adrenergic agonist moiety are connected covalently via a linker, and the link includes an ester bond, an amide bond, a carbamate bond, or a combination thereof.
-
公开(公告)号:US20230210770A1
公开(公告)日:2023-07-06
申请号:US17927796
申请日:2021-05-11
申请人: ADS THERAPEUTICS LLC
发明人: Jinsong NI , Rong YANG
IPC分类号: A61K9/107 , A61K31/4439 , A61K31/506 , A61K31/496 , A61P27/06 , A61K9/00
CPC分类号: A61K9/107 , A61K31/4439 , A61K31/506 , A61K31/496 , A61P27/06 , A61K9/0048
摘要: A topical ophthalmological composition includes a multikinase inhibitor as an active pharmaceutical ingredient, and perfluorohexyloctane (F6H8) as a liquid vehicle. The multikinase inhibitor inhibits vascular endothelial growth factor receptors (VEGFRs). A method for treating an ophthalmological disorder includes: providing a topical ophthalmological composition containing a multikinase inhibitor at a concentration of about 0.01-10% (w/v); and treating a patient with the topical ophthalmological composition for treating the ophthalmological disorder.
-
-
-
-
-